Skip to main content
. 2016 May 6;7(23):35313–35326. doi: 10.18632/oncotarget.9204

Figure 4.

Figure 4

EGCG treatment decreases promoter methylation of RXRα A. in CIMP+ lines (HCT116, SW48) with moderate decrease in (HT29). CIMP- lines (SW480) show little change in promoter methylation (p<0.001 HCT116 vs HT29 & SW480, p<0.01 SW48 vs HT29 & SW480). B&C. Fold change in RXRα expression in a dose dependent manner and time (48hr & 72hr) dependent manner (**** p<0.001; **p<0.01; *p<0.05).